Compare TLS & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLS | RCKT |
|---|---|---|
| Founded | 1969 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.1M | 534.2M |
| IPO Year | 2020 | N/A |
| Metric | TLS | RCKT |
|---|---|---|
| Price | $4.01 | $4.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $7.90 | ★ $29.65 |
| AVG Volume (30 Days) | 892.8K | ★ 2.7M |
| Earning Date | 03-16-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $164,805,000.00 | N/A |
| Revenue This Year | $19.69 | N/A |
| Revenue Next Year | $19.33 | $97.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 52.21 | N/A |
| 52 Week Low | $1.83 | $2.19 |
| 52 Week High | $8.36 | $8.80 |
| Indicator | TLS | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 40.22 | 50.69 |
| Support Level | $3.82 | $2.99 |
| Resistance Level | $5.95 | $5.39 |
| Average True Range (ATR) | 0.34 | 0.38 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 14.69 | 22.09 |
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.